This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Biobanking Remove Drugs Remove Hormones Related Topics
Gene Silencing Insulin Gene RNA DNA Genomics Genome Clinical Trials Containment Clinical Development More Related Topics >
article thumbnail

Alnylam finds belly fat gene and drug target in UK Biobank study

pharmaphorum

JULY 28, 2022

The finding came from an analysis of sequencing data from more than 360,000 individuals in the UK Biobank , which contains genetic and health information from half a million UK participants. The post Alnylam finds belly fat gene and drug target in UK Biobank study appeared first on. Image by Bruno /Germany from Pixabay .

Biobanking 52
Biobanking Gene Gene Silencing Drugs 52
article thumbnail

Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting

The Pharma Data

APRIL 11, 2023

In the New Drugs on the Horizon session at AACR, Bayer will present preclinical data on its novel selective diacylglycerol kinase (DGK) zeta inhibitor BAY 2965501, which is under Phase 1 clinical evaluation. These results, along with a mathematical model-informed approach have supported the currently ongoing dose expansion for BAY 2416964.

Research 40
Research Clinical Trials Clinical Trials Trials 40
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024